BioSpace News Archive

Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience has added a new clinical research program for the treatment of Traumatic Brain Injury with AP-188.

Evoke Pharma, Inc. today announced that its abstract entitled “Reducing Real-World Healthcare Resource Utilization For Patients With Diabetic Gastroparesis (DGP) Treated with Metoclopramide Nasal Spray Versus Oral Metoclopramide” has been selected for the plenary lecture presentation at the upcoming Digestive Disease Week (DDW) 2023.

TriSalus Life Sciences ® , Inc. today announced that James “Jim” Alecxih has joined the Company in the newly created role of President, Device Technology Business.

This is the first time the FDA has given IND approval for a Phase IIb study of a short-acting psychedelic like 5-MeO-DMT (Mebufotenin).

Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its third “Conversations” video podcast, featuring a discussion with two Lewy body dementia caregivers, who are also passionate advocates for the second most common and devastating form of dementia.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023 and will provide a business update.

Biohaven Ltd. (NYSE: BHVN; “Biohaven”) announced today that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for taldefgrobep alfa, a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA).

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the late-breaker presentation of a patient case study from the Phase 3 Part A clinical trial of nomacopan in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).

89bio, Inc. (Nasdaq: ETNB) today announced additional pegozafermin data from the Phase 2 ENTRIGUE study in severe hypertriglyceridemia (SHTG) will be presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Congress of Cardiology to be held March 4-6, 2023 in New Orleans.

Esperas Pharma, Inc., a company based in Montréal, Québec, announced a follow-on investment by TVM Capital Life Science through its fund TVM Life Science Innovation I SCSp and the Fonds de solidarité FTQ.